Terumo/Therakos Sign Distribution Deal For Australia/New Zealand

Terumo BCT has entered into a business relationship with Therakos to be the exclusive distributor in Australia and New Zealand of Therakos' Uvar XTS and Cellex photopheresis systems, which physicians use to treat patients with diseases of the immune system. Terumo will begin distributing Therakos products in mid-January 2014.

Therakos' photopheresis systems are claimed to be the only integrated systems for extracorporeal photopheresis, a leukapheresis-based immunomodulatory therapy that has been approved by the FDA for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma unresponsive to other forms of treatment.

Sandra Thompson, Chief Operating Officer, Therakos, stated that bringing together the company's clinical experience with the market presence and infrastructure of Terumo in Australia and New Zealand will provide for greater access and treatment options for patients.

This article is tagged to:
Related sectors of this article: Medical Devices, MIW, Supply Chain - Medical Devices, Agreements - Medical Devices
Geography: Australia, United Kingdom, Japan, New Zealand

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.